News from DURECT Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 01, 2017, 16:05 ET DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate Update

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2017 and provided a corporate update....


Oct 26, 2017, 16:54 ET DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2017 financial results press release, you are invited to listen to a...


Oct 19, 2017, 17:57 ET DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint

DURECT Corporation (Nasdaq: DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR® (SABER®-Bupivacaine), did not meet its...


Oct 02, 2017, 02:05 ET DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement

DURECT Corporation (Nasdaq: DRRX) today announced a patent purchase agreement with Indivior UK Limited, an affiliate of Indivior PLC (LON: INDV),...


Sep 20, 2017, 08:00 ET DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development

DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Myriam Theeuwes has joined DURECT as Senior Vice President, Clinical Development. Dr....


Sep 05, 2017, 16:15 ET DURECT to Participate in Upcoming Healthcare Conferences

DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming investment conferences. -...


Aug 08, 2017, 16:05 ET DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate Update

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2017 and provided a corporate update....


Aug 08, 2017, 08:30 ET ORADUR®-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan

CUPERTINO, Calif., Aug. 8, 2017 /PRNewswire/-- DURECT Corporation (Nasdaq: DRRX) today announced that Orient Pharma Co., Ltd., its licensee for...


Aug 01, 2017, 16:15 ET DURECT Corporation Invites You to Join its Second Quarter 2017 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2017 financial results press release, you are invited to listen to a...


Jun 22, 2017, 07:00 ET DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR®

DURECT Corporation (Nasdaq: DRRX) today announced that patient enrollment has been completed in PERSIST, the pivotal Phase 3 clinical trial of...


Jun 19, 2017, 07:00 ET DURECT's Collaboration with Sandoz Clears HSR Review and is Effective

DURECT Corporation (Nasdaq: DRRX) today announced that the previously disclosed development and commercialization agreement with Sandoz AG, a...


May 10, 2017, 16:05 ET DURECT Corporation Announces First Quarter 2017 Financial Results and Provides Corporate Update

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2017 and provided a corporate update....


May 08, 2017, 07:00 ET DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States

DURECT Corporation (Nasdaq: DRRX) today announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS),...


May 04, 2017, 16:30 ET DURECT Corporation Invites You to Join its First Quarter 2017 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2017 financial results press release, you are invited to listen to a...


Apr 24, 2017, 08:00 ET DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and...


Apr 17, 2017, 08:00 ET DURECT to Present Clinical Data at the International Liver Congress™ 2017

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and...


Apr 03, 2017, 07:30 ET DURECT to Present at the H.C. Wainwright NASH Investor Conference

DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and Chief Executive Officer, will be presenting at the H.C. Wainwright...


Mar 14, 2017, 16:02 ET DURECT Corporation Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2016 and provided a corporate...


Feb 24, 2017, 16:55 ET DURECT Corporation Invites You to Join its Fourth Quarter 2016 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2016 financial results press release, you are invited to listen to a...


Jan 30, 2017, 08:00 ET DURECT Corporation Announces Update on DUR-928 Development Program

DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program. DUR-928, our Epigenetic Regulator Program's lead...


Oct 31, 2016, 16:03 ET DURECT Corporation Announces Third Quarter 2016 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2016. Total revenues were $3.7 million and net loss...


Oct 31, 2016, 16:02 ET DURECT Corporation Announces Update on DUR-928 Development Program

DURECT Corporation (Nasdaq: DRRX) today provided an update on the DUR-928 development program including a description of data from the first cohort...


Oct 21, 2016, 16:30 ET DURECT Corporation Invites You to Join its Third Quarter 2016 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2016 financial results press release, you are invited to listen to a...


Sep 26, 2016, 07:05 ET DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII

 DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has received a Complete Response Letter...


Sep 06, 2016, 08:00 ET DURECT to Present at the Rodman & Renshaw Global Investment Conference

DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at the Rodman & Renshaw Global...